+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Antidiabetics Market Analysis: By Drugs Type; and By Geography - With Forecast 2016-2021

  • ID: 3920151
  • Report
  • February 2016
  • Region: Global
  • 139 pages
  • IndustryARC
1 of 3
The anti-diabetics are the drugs (also known as oral hypoglycemic/antihyperglycemic agents), which are used for treatment of diabetes mellitus. Diabetes mellitus also commonly known as diabetes metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both which is caused by either the pancreas not producing enough insulin or the cells of the body not responding properly to the insulin produced. According to the International Diabetes Foundation (IDF), globally 415 million people are diagnosed with diabetes which is expected to grow to 640 million by 2040. This significant increase in the number of diabetic population is expected to be the prime growth driver for the global antidiabetics market in the near future.

This report identifies the Antidiabetics market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to Antidiabetics market.

Globally North America dominated the market for antidiabetics in 2015 due to high penetration and adoption of antidiabetics drugs in the medical system of the region coupled with high healthcare expenditures, patient awareness levels and advanced healthcare infrastructure. North America was followed by Europe and Asia-Pacific as the second and third largest markets respectively for antidiabetics in 2015. Demand for Antidiabetics in Asia-Pacific is expected to witness fastest growth in the near future due to increasing diabetic population in the region coupled with increasing awareness and developing medical infrastructure in the region.

This report on global Antidiabetics is segmented on the basis of various types of Antidiabetics, treated disease and market size in various geographical regions.

On the basis of types of antidiabetics drugs this report classified as follows covering all major types of antidiabetics drugs as follows: Insulin (Rapid acting, Long acting, Premixed, Premixed analog, Short acting, Intermediate acting, Antidiabetics, Alpha-glucosidase inhibitors), Biguanides (Sulphonylureas, GLP-1 agonist, Meglitinides, DPP-4 inhibitors, SGLT – 2, Thiazolodinediones)
This is report has been further segmented into major regions, which includes detailed analysis of each region such as North America, Europe, Asia-Pacific (APAC) and Rest of the World (RoW) covering all the major country level markets for antidiabetics in each of the region.

This report identifies all the major companies operating in the global Antidiabetics market. Some of the major companies’ profiles in detail are as follows:

Boehringer Ingelheim GmbH
Sanofi S.A.
Astra Zeneca plc
Eli Lilly & Co
Johnson & Johnson
Novartis Pharmaceuticals AG
Please Note: The report is to be delivered in 1-2 working days after an order is placed.
Note: Product cover images may vary from those shown
2 of 3
1. Antidiabetics – Market Overview

2. Executive Summary

3. Antidiabetics Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.2.1. Product Benchmarking
3.2.2. End User Profiling
3.2.3. Top 5 Financials Analysis

4. Antidiabetics – Market Forces
4.1. Drivers
4.1.1. Increasing global population with obesity and diabetics
4.2. Restraints
4.3. Opportunities
4.3.1. Strong pipe line for diabetics drugs and investment in R&D activities
4.4. Challenges
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Degree of Competition

5. Antidiabetics – Strategic Analysis
5.1. Value Chain Analysis
5.2. Pricing Analysis
5.3. Opportunities Analysis
5.4. Product/Market Life Cycle Analysis
5.5. Suppliers and Distributors

6. Global Antidiabetics Market, By Drugs Type (2014-2021)
6.1. Insulin
6.1.1. Rapid acting
6.1.2. Long acting
6.1.3. Premixed
6.1.4. Premixed analog
6.1.5. Short acting
6.1.6. Intermediate acting
6.1.7. Antidiabetics
6.1.8. Alpha-glucosidase inhibitors
6.2. Biguanides
6.2.1. Sulphonylureas
6.2.2. GLP-1 agonist
6.2.3. Meglitinides
6.2.4. DPP-4 inhibitors
6.2.5. SGLT – 2
6.2.6. Thiazolodinediones

7. Global Antidiabetics Market, By Geography (2014-2021)
7.1. Europe
7.1.1. Germany
7.1.2. France
7.1.3. Italy
7.1.4. Spain
7.1.5. Russia
7.1.6. U.K.
7.1.7. Rest of Europe
7.2. Asia Pacific
7.2.1. China
7.2.2. India
7.2.3. Japan
7.2.4. South Korea
7.2.5. Rest of Asia-Pacific
7.3. North America
7.3.1. U.S.
7.3.2. Canada
7.3.3. Mexico
7.4. Rest of the World (RoW)
7.4.1. Brazil
7.4.2. Rest of RoW

8. Antidiabetics – Market Entropy
8.1. Expansion
8.2. Technological Developments
8.3. Merger & Acquisitions, and Joint Ventures
8.4. Supply- Contract

9. Company Profiles (Top 10 Companies)
9.1. Boehringer Ingelheim GmbH
9.1.1. Introduction
9.1.2. Financials
9.1.3. Key Insights
9.1.4. Key Strategy
9.1.5. Product Portfolio
9.1.6. SWOT Analysis
9.2. Sanofi S.A.
9.2.1. Introduction
9.2.2. Financials
9.2.3. Key Insights
9.2.4. Key Strategy
9.2.5. Product Portfolio
9.2.6. SWOT Analysis
9.3. Astra Zeneca plc
9.3.1. Introduction
9.3.2. Financials
9.3.3. Key Insights
9.3.4. Key Strategy
9.3.5. Product Portfolio
9.3.6. SWOT Analysis
9.4. Eli Lilly & Co
9.4.1. Introduction
9.4.2. Financials
9.4.3. Key Insights
9.4.4. Key Strategy
9.4.5. Product Portfolio
9.4.6. SWOT Analysis
9.5. Johnson & Johnson
9.5.1. Introduction
9.5.2. Financials
9.5.3. Key Insights
9.5.4. Key Strategy
9.5.5. Product Portfolio
9.5.6. SWOT Analysis
9.6. Novartis Pharmaceuticals AG
9.6.1. Introduction
9.6.2. Financials
9.6.3. Key Insights
9.6.4. Key Strategy
9.6.5. Product Portfolio
9.6.6. SWOT Analysis
9.7. Novo Nordisk A/S
9.7.1. Introduction
9.7.2. Financials
9.7.3. Key Insights
9.7.4. Key Strategy
9.7.5. Product Portfolio
9.7.6. SWOT Analysis
9.8. Mankind Pharma Ltd.
9.8.1. Introduction
9.8.2. Financials
9.8.3. Key Insights
9.8.4. Key Strategy
9.8.5. Product Portfolio
9.8.6. SWOT Analysis
9.9. Teva Pharmaceutical Industries Ltd.
9.9.1. Introduction
9.9.2. Financials
9.9.3. Key Insights
9.9.4. Key Strategy
9.9.5. Product Portfolio
9.9.6. SWOT Analysis
9.10. Merck & Co. Inc.
9.10.1. Introduction
9.10.2. Financials
9.10.3. Key Insights
9.10.4. Key Strategy
9.10.5. Product Portfolio
9.10.6. SWOT Analysis
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"

10. Appendix
10.1. Abbreviations
10.2. Sources
10.3. Research Methodology
10.4. Expert Insights
Note: Product cover images may vary from those shown
3 of 3


4 of 3